Phospholipase C beta 1 (PLCβ1) (PLCβ1)

Phospholipase C beta 1 (PLCβ1) is a critical signaling enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two essential second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [1]. This process is primarily triggered by the activation of G protein-coupled receptors (GPCRs) associated with the Gq/11 family, leading to intracellular calcium mobilization and protein kinase C activation [1]. PLCβ1 is predominantly expressed in the central nervous system, where it is vital for synaptic plasticity, neuronal development, and cognitive function [2]. Mutations or deletions in the PLCB1 gene are strongly associated with severe neurological disorders, including early infantile epileptic encephalopathy type 12 (EIEE12) and schizophrenia [2]. In oncology, particularly in myelodysplastic syndromes (MDS), PLCβ1 mRNA expression levels serve as a predictive biomarker for the efficacy of hypomethylating agents like azacitidine [3, 4]. While direct pharmacological inhibitors like U73122 exist for research purposes, therapeutic strategies often focus on modulating its expression or downstream signaling pathways [5].

Other names

PLCB1Phosphoinositide phospholipase C-beta-1PLC-beta-1EIEE121-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1

PLCβ1 catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [1]. Drugs like azacitidine indirectly target PLCβ1 by inducing its mRNA expression through the demethylation of its promoter, which is often silenced in myelodysplastic syndromes [3, 4]. Experimental inhibitors like U73122 directly bind to and inhibit the phospholipase activity of the protein [5].